Karyopharm Therapeutics Inc.
- UEI
- JF64YMCE9V63
- CAGE
- 7FSV2
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- karyopharm.com
- Founded
- 2008
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Selinexor | Veterans Integrated Service Network 12 (VHA) | $0 |
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Vanderbilt University Medical Center | R01CA262287 | $5,586 | |
| Vanderbilt University Medical Center | R01CA262287 | $5,492 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Incyte Corporation | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
| TG Therapeutics Inc. | Morrisville, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Fennec Pharmaceuticals, Inc. | Durham, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Bristol-Myers Squibb Company | Lawrence Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Servier Pharmaceuticals LLC | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Karyopharm Therapeutics Inc., doing business as Karyopharm, is an innovation driven pharmaceutical company focused on the discovery, development, and commercialization of medicines to improve the lives of patients with cancer. The company provides pharmaceutical products and services to the federal government through Federal Supply Schedule (FSS) contracts and associated delivery orders from agencies like the Department of Veterans Affairs (VA).
Karyopharm has been awarded a $0 firm fixed price delivery order by the VA's Veterans Health Administration to provide the drug SELINEXOR to locations in Pittsburgh, Pennsylvania by October 31, 2019. The delivery order was issued under Karyopharm's FSS contract to supply hematology-related drugs and pharmaceuticals in support of the VA's veteran healthcare mission. Karyopharm also holds an FSS contract, with a potential value of $4 million, to provide hematology-related drugs and pharmaceutical products to VA facilities through March 2025. As a multiple award contract, Karyopharm can compete for task orders to supply their products to VA hospitals and clinics nationwide.
Karyopharm has not received any prime federal grants but was named as a sub recipient on a grant from Vanderbilt University Medical Center to study BCL2 inhibitors in myeloid malignancies. Karyopharm is providing SINE compounds to test in combinations with other therapies on primary AML patient samples. This supports the overall grant's goal of developing personalized therapies for hematologic cancers.
Additionally, Karyopharm was awarded an interim FSS agreement by the VA, with a potential value of $25,000, to supply hematology-related pharmaceuticals. While expired in February 2020, this paved the way for the larger $4 million FSS contract referenced above. Under its active FSS contract, Karyopharm can supply its full catalog of hematologic cancer drugs to VA facilities placing orders through March 2025. As a pharmaceutical company focused on developing cancer treatments, Karyopharm leverages its FSS contracts as a vehicle for providing innovative therapies to veterans in need.
Quick answers
Is Karyopharm Therapeutics Inc. registered in SAM.gov?
Karyopharm Therapeutics Inc.'s SAM.gov registration expired on September 18, 2026.
Which contract vehicles does Karyopharm Therapeutics Inc. hold?
Karyopharm Therapeutics Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Karyopharm Therapeutics Inc.'s most recent federal award?
Karyopharm Therapeutics Inc.'s most recent federal contract award is Selinexor (36C25220F0040), from Veterans Integrated Service Network 12 (VHA), on October 8, 2019.
On GovTribe
See Karyopharm Therapeutics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors